32: The Future of Glycoengineering: Trends Unveiled w/ Thomas Rexer - Part 2

Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation - A podcast by David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist

Send us a textDiscover the hurdles and breakthroughs in glycoengineering, including the high costs of activated sugars.Thomas Rexer, CTO of eversyn, a spin-off of the Max Planck Institute Magdeburg, unveils eversyn's multi-step biocatalysis process, designed to significantly drive down costs and make in vitro glycoengineering more accessible on a large scale.Key Insights:Uncover the power of multistep biocatalysis in driving down costs and making in vitro glycoengineering more accessible.Brid...